Cargando…
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease in which many processes are detected including (neuro)inflammation. Many drugs have been tested for ALS in clinical trials but most have failed to reach their primary endpoints. The development and inclusion of different...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785449/ https://www.ncbi.nlm.nih.gov/pubmed/35073950 http://dx.doi.org/10.1186/s13024-022-00515-1 |
_version_ | 1784638966781181952 |
---|---|
author | Staats, Kim A. Borchelt, David R. Tansey, Malú Gámez Wymer, James |
author_facet | Staats, Kim A. Borchelt, David R. Tansey, Malú Gámez Wymer, James |
author_sort | Staats, Kim A. |
collection | PubMed |
description | Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease in which many processes are detected including (neuro)inflammation. Many drugs have been tested for ALS in clinical trials but most have failed to reach their primary endpoints. The development and inclusion of different types of biomarkers in diagnosis and clinical trials can assist in determining target engagement of a drug, in distinguishing between ALS and other diseases, and in predicting disease progression rate, drug responsiveness, or an adverse event. Ideally, among other characteristics, a biomarker in ALS correlates highly with a disease process in the central nervous system or with disease progression and is conveniently obtained in a peripheral tissue. Here, we describe the state of biomarkers of inflammation in ALS by focusing on peripherally detectable and cellular responses from blood cells, and provide new (combinatorial) directions for exploration that are now feasible due to technological advancements. |
format | Online Article Text |
id | pubmed-8785449 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87854492022-01-24 Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis Staats, Kim A. Borchelt, David R. Tansey, Malú Gámez Wymer, James Mol Neurodegener Review Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease in which many processes are detected including (neuro)inflammation. Many drugs have been tested for ALS in clinical trials but most have failed to reach their primary endpoints. The development and inclusion of different types of biomarkers in diagnosis and clinical trials can assist in determining target engagement of a drug, in distinguishing between ALS and other diseases, and in predicting disease progression rate, drug responsiveness, or an adverse event. Ideally, among other characteristics, a biomarker in ALS correlates highly with a disease process in the central nervous system or with disease progression and is conveniently obtained in a peripheral tissue. Here, we describe the state of biomarkers of inflammation in ALS by focusing on peripherally detectable and cellular responses from blood cells, and provide new (combinatorial) directions for exploration that are now feasible due to technological advancements. BioMed Central 2022-01-24 /pmc/articles/PMC8785449/ /pubmed/35073950 http://dx.doi.org/10.1186/s13024-022-00515-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Staats, Kim A. Borchelt, David R. Tansey, Malú Gámez Wymer, James Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis |
title | Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis |
title_full | Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis |
title_fullStr | Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis |
title_full_unstemmed | Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis |
title_short | Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis |
title_sort | blood-based biomarkers of inflammation in amyotrophic lateral sclerosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785449/ https://www.ncbi.nlm.nih.gov/pubmed/35073950 http://dx.doi.org/10.1186/s13024-022-00515-1 |
work_keys_str_mv | AT staatskima bloodbasedbiomarkersofinflammationinamyotrophiclateralsclerosis AT borcheltdavidr bloodbasedbiomarkersofinflammationinamyotrophiclateralsclerosis AT tanseymalugamez bloodbasedbiomarkersofinflammationinamyotrophiclateralsclerosis AT wymerjames bloodbasedbiomarkersofinflammationinamyotrophiclateralsclerosis |